<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04953923</url>
  </required_header>
  <id_info>
    <org_study_id>E7727-02</org_study_id>
    <nct_id>NCT04953923</nct_id>
  </id_info>
  <brief_title>Thorough QT Assessment of Cedazuridine in Healthy Subjects</brief_title>
  <official_title>A Randomized, Double-blinded, Double-dummy, Placebo-controlled Thorough QTC Study With Single Oral Doses of Cedazuridine in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astex Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astex Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the effect of therapeutic and supratherapeutic oral doses&#xD;
      of cedazuridine on cardiac repolarization, as detected by QTc in healthy subjects, in&#xD;
      accordance with regulatory guidelines. Moxifloxacin will be used to validate the study. Study&#xD;
      duration per participant is approximately 20 days.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2021</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in QTcF</measure>
    <time_frame>Baseline and Day 20</time_frame>
    <description>Change from baseline in QTcF following single therapeutic and supratherapeutic doses of cedazuridine</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in QTcF</measure>
    <time_frame>Baseline and Day 20</time_frame>
    <description>Change from baseline in QTcF following cedazuridine-epimer and moxifloxacin administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Participants with adverse events</measure>
    <time_frame>Up to Day 20</time_frame>
    <description>Number of participants with adverse events following single therapeutic and supratherapeutic doses of cedazuridine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in heart rate</measure>
    <time_frame>Baseline and Day 20</time_frame>
    <description>Change from baseline in heart rate following single therapeutic and supratherapeutic doses of cedazuridine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in PR interval of the electrocardiogram (ECG)</measure>
    <time_frame>Baseline and Day 20</time_frame>
    <description>Change from baseline in PR interval of the ECG following single therapeutic and supratherapeutic doses of cedazuridine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in QRS interval of the electrocardiogram (ECG)</measure>
    <time_frame>Baseline and Day 20</time_frame>
    <description>Change from baseline in QRS interval of the ECG following single therapeutic and supratherapeutic doses of cedazuridine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in T-wave morphology</measure>
    <time_frame>Baseline to Day 20</time_frame>
    <description>Change from baseline in treatment-emergent T-wave morphology following single therapeutic and supratherapeutic doses of cedazuridine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter: Cmax</measure>
    <time_frame>Up to Day 20</time_frame>
    <description>Cmax is the maximum observed plasma concentration of cedazuridine, cedazuridine-epimer, and moxifloxacin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter: Tmax</measure>
    <time_frame>Up to Day 20</time_frame>
    <description>Tmax is the time to maximum observed plasma concentration of cedazuridine, cedazuridine-epimer, and moxifloxacin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter: AUClast</measure>
    <time_frame>Up to Day 20</time_frame>
    <description>Area under the curve (AUC) from time 0 to time of last measurable concentration of cedazuridine, cedazuridine-epimer, and moxifloxacin</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cedazuridine at a therapeutic dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cedazuridine at a supratherapeutic dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo control</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Moxifloxacin positive control</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cedazuridine</intervention_name>
    <description>Tablet for oral administration</description>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_label>Treatment B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Capsule for oral administration</description>
    <arm_group_label>Treatment C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <description>Tablet for oral administration</description>
    <arm_group_label>Treatment D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female who is not of childbearing potential&#xD;
&#xD;
          -  Body mass index of 18.0 to 32.0 kg/m^2, inclusive&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  QTcF &gt;450 msec at screening&#xD;
&#xD;
          -  Clinically relevant abnormalities in conduction parameters; or if PR interval &gt; 200&#xD;
             msec, QRS duration &gt; 110 msec, or bradycardia or tachycardia (HR &lt;45 bpm or &gt;100 bpm)&#xD;
&#xD;
          -  History or presence of hypokalemia, hypomagnesemia, or hypocalcemia&#xD;
&#xD;
          -  Risk factors for Torsades de Pointes (TdP) (eg, congenital deafness, heart failure,&#xD;
             cardiomyopathy, concomitant medications known to cause QTc prolongation) within a&#xD;
             washout of at least 30 days&#xD;
&#xD;
          -  Family history of Long QT Syndrome or family history of TdP&#xD;
&#xD;
          -  Sick sinus syndrome, atrioventricular block (any degree)&#xD;
&#xD;
          -  Myocardial infarction, pulmonary congestion, cardiac arrhythmia, prolonged QT&#xD;
             interval, or conduction abnormalities&#xD;
&#xD;
          -  Repeated or frequent syncope or vasovagal episodes&#xD;
&#xD;
          -  Resuscitated arrest possibly due to TdP; hypertension, angina, or severe peripheral&#xD;
             arterial circulatory disorders&#xD;
&#xD;
          -  Use of concomitant medications that prolong the QT/QTc interval&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>PRA Health Sciences</name>
      <address>
        <city>Groningen</city>
        <zip>9472NZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerben Gotlieb</last_name>
      <phone>31 50 4022 672</phone>
      <email>gotliebgerben@prahs.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 30, 2021</study_first_submitted>
  <study_first_submitted_qc>June 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 8, 2021</study_first_posted>
  <last_update_submitted>August 3, 2021</last_update_submitted>
  <last_update_submitted_qc>August 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

